Rezvilutamide
Clinical data | |
---|---|
Other names | SHR3680 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C22H20F3N3O4S |
Molar mass | 479.47 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Rezvilutamide (INN;[1][2] developmental code name SHR3680) is a nonsteroidal antiandrogen which is under development by Jiangsu Hengrui Medicine for the treatment of prostate cancer and breast cancer.[3][4] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][4] As of October 2020, rezvilutamide is in phase 3 clinical trials for prostate cancer.[3] Other structural analogues of rezvilutamide besides enzalutamide include apalutamide and proxalutamide.
See also[]
- List of investigational hormonal agents § Androgenics
References[]
- ^ "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
- ^ a b c "SHR 3680". AdisInsight.
- ^ a b Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90.
Categories:
- Benzonitriles
- Diols
- Experimental cancer drugs
- Hormonal antineoplastic drugs
- Ketones
- Imidazolidines
- Nonsteroidal antiandrogens
- Sulfur compounds
- Trifluoromethyl compounds
- Genito-urinary system drug stubs